Abstract
ObjectiveCOVID19 has caused a global and ongoing pandemic. The need for population seroconversion data is apparent to monitor and respond to the pandemic. Using a lateral flow assay (LFA) testing platform, the seropositivity in 63 New York Blood Center (NYBC) Convelescent Plasma (CP) donor samples were evaluated for the presence of COVID19 specific IgG and IgM.ResultsCP donors showed diverse antibody result. Convalescent donor plasma contains SARS-CoV-2 specific antibodies. Weak antibody bands may identify low titer CP donors. LFA tests can identify antibody positive individuals that have recovered from COVID19. Confirming suspected cases using antibody detection could help inform the patient and the community as to the relative risk to future exposure and a better understanding of disease exposure.
Highlights
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has caused over 4012,000 infections and > 32,000 deaths in New York State alone [1]
We report the sensitivity and specificity of C lungene® SARS-CoV-2 Immunoglobulin G (IgG)/Immunoglobulin M (IgM) Rapid Test Cassettes in determining the presence of binding antibodies in convalescent plasma (CP) donor samples with previously documented Severe acute respiratory syndrome coronavirus 2 (COVID19)
88.9% (56/63) of CP donors were considered positive. 87.3% (55/63) of CP donors were positive for IgG and 50.8% (32/63) of CP donors were positive for IgM (Fig. 2a, b)
Summary
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has caused over 4012,000 infections and > 32,000 deaths in New York State alone [1]. Seroconversion, the process in which a patient accumulates antigen-specific antibodies against an epitope, is the first step towards the development of adaptive immunity against pathogens. It is not an assurance of protection against future infections, positive seroconversion is an informative measure of previous viral infectivity. A crucial step in understanding the test characteristics is to ensure the assay detects antibodies in individuals with a previous documented disease. Assay characteristics such as antigen target (nucleocapsid and/or spike glycoprotein), total (IgG and IgM) versus IgG only, and their sensitivity and specificity are important in defining seroconversion rates [5]. More studies with various antibody tests are needed to understand seroconversion of an infected population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
